Debora Santoro

Learn More
BACKGROUND Tobramycin nebuliser solution (TNS) is indicated for maintenance therapy in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) infections. Adherence to recommended therapy in CF has always been a challenge and new generation nebulisers are increasingly used "off label" to reduce the time required for inhalation, potentially(More)
INTRODUCTION Aerosolized tobramycin is a standard of care for chronic Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis (CF). OBJECTIVES The long-term safety and efficacy of intermittent (28-day "on"/"off" cycles) inhaled tobramycin nebulization solution 300 mg/4 ml (TNS4, Bramitob(®)/Bethkis(®)) was assessed over 56 weeks in CF(More)
In hemodialysis patients, vertebral fractures were associated with elevated sclerostin levels, suggesting that sclerostin could reflect bone fragility in these patients. Fragility fractures are common in hemodialysis patients. The aims of our study were to determine the prevalence of vertebral fracture and analyze associations between sclerostin serum(More)
A long term follow up of thirty two patients operated on for Kienböck's disease of the semilunar bone at the Istituto Ortopedico Toscano in the last twenty eight years has been carried out. Three types of operation were performed; excision of the semilunar, lengthening of the ulna, and shortening of the radius. The best results were obtained from shortening(More)
OBJECTIVE CHF5633 (Chiesi Farmaceutici S.p.A., Parma, Italy) is the first fully synthetic surfactant enriched by peptide analogues of two human surfactant proteins. We planned to assess safety and tolerability of CHF5633 and explore preliminary efficacy. DESIGN Multicentre cohort study. PATIENTS Forty infants from 27+0 to 33+6 weeks gestation with(More)
Fifty nine cases of open diaphyseal fractures of the long bones treated by rigid osteosynthesis were examined with reference to their course and outcome in relation to whether the operation was immediate of deferred. No significant differences arose as between the two groups of cases. It thus appears that the timing of the operation has no important(More)
CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases. The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model. Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who(More)
  • 1